 |
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the 147th Annual Meeting of the American Neurological Association (ANA) on October 24, 2022. For over 140 years, the ANA has been the premier professional society of academic neurologists and neuroscientists devoted to understanding and treating diseases of the nervous system.
The presentation evaluated different methods of measuring the volume of brain structures affected in individuals with Multiple System Atrophy (MSA) and Parkinson's' disease versus healthy controls. The poster, entitled Deep Learning Segmentation Improves Precision of Volume Assessment of Subcortical Structures in early MSA, evaluated the accuracy of MRI scans on three different areas of the basal ganglia section of the brain utilizing three different techniques.
"Our bioMUSE natural history study continues to produce meaningful data to guide our Phase 2 trial by providing valuable insight into the diagnosis and biomarkers of MSA," said David Stamler, M.D., Chief Executive Officer, Alterity. "In particular, the poster presented at ANA found meaningful differences in methods to measure brain volume in MSA patients. This work will allow for greater precision in defining affected brain structures, an essential step for quantifying changes in MSA, such as tissue atrophy and iron deposition."
The study enrolled 21 individuals with early stage MSA based on neurological assessment. The study concluded that deep-learning segmentation, a form of artificial intelligence, outperforms the commonly used methods FSL-FIRST and Joint Label Fusion for analyzing brain MRI scans in MSA patients. This improvement was observed in subcortical brain regions with notable MSA pathology. MSA-related pathological changes hinder the precision of automatic segmentation from FSL-FIRST. In addition, in early MSA, significant reductions in putamen and pallidum volume were observed compared to healthy controls, and in pallidum volume compared to Parkinson's disease.
About ATH434
Alterity's lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 has been granted Orphan designation for the treatment of MSA by the U.S. FDA and the European Commission.
About bioMUSE
Biomarkers of progression in Multiple System Atrophy (bioMUSE) is an ongoing, natural history study that aims to track the progression of patients with MSA, a Parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, MD, Associate Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity's Phase 2 clinical trial and will be expanded to include a total of 20 patients with MSA. The ongoing study will continue to provide vital information on early stage MSA patients, inform the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and deliver clinical data to characterize disease progression in a patient population that mirrors those to be enrolled in the Phase 2 clinical trial.
About Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects approximately 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.[1]
[1]National Institute of Health: Neurological Disorders and Stroke, Multiple System Atrophy Fact Sheet |
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-announces-presentation-of-mri-data-from-the-biomuse-natural-history-study-at-the-american-neurological-association-annual-meeting-301659489.html
